Name: ONC206
Brand: Selleck Chemicals
SKU: S6853
Rating: 5 (2 reviews)

ONC206 is a selective antagonist of DRD2/3/4 with broad-spectrum anti-tumor activity.

ONC206 Chemical Structure

CAS: 1638178-87-6

Selleck's ONC206 has been cited by 2 publications

Purity & Quality Control

Batch: Purity: 99.93%

99.93

ONC206 Related Products

Related Targets	D1 receptor D2 receptor D3 receptor D5 receptor DAT D4 receptor	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

Dopamine Receptor Signaling Pathway

Choose Selective Dopamine Receptor Inhibitors

Biological Activity

Description

ONC206 is a selective antagonist of DRD2/3/4 with broad-spectrum anti-tumor activity.

Targets

DRD2 ^[1]

In vitro
In vitro	ONC206 is a ClpP agonist regarding the requirement of high doses (50–130 mg/kg) to achieve in vivo efficacy. ^[2]
Cell Research	Cell lines	SUM159 and MDA‐MB‐231 (WT and CLPP‐KO) cell lines
	Concentrations	--
	Incubation Time	72 h
	Method	Cells were treated with indicated drug concentrations for 72 h and imaged following addition of Hoechst stain. (Data sourced from selleck products)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT04732065	Recruiting	Diffuse Midline Glioma (DMG)\|Glioblastoma\|Recurrent Ependymoma\|Recurrent Malignant Central Nervous System Neoplasm\|Spinal Cord Glioma\|World Health Organization (WHO) Grade III Glioma\|CNS Tumor\|Central Nervous System Tumor	Sabine Mueller MD PhD\|Chimerix\|Mithil Prasad Foundation\|Storm the Heavens Fund\|The ChadTough Defeat DIPG Foundation\|National Cancer Institute (NCI)\|University of California San Francisco	August 23 2021	Phase 1
NCT04541082	Recruiting	Central Nervous System Neoplasms\|Glioblastoma\|Gliosarcoma Adult\|Anaplastic Oligodendroglioma\|Anaplastic Astrocytoma\|Pilocytic Astrocytoma\|Oligodendroglioma\|Gliomatosis Cerebri\|Pleomorphic Xanthoastrocytoma\|Anaplastic Pleomorphic Xanthoastrocytoma\|Diffuse Midline Glioma H3 K27M-Mutant\|Ependymoma\|Ependymoma Anaplastic\|Medulloblastoma\|Teratoid Rhabdoid Tumor\|Neuroectodermal Tumors Primitive\|Neuroectodermal Tumors\|Anaplastic Meningioma\|Atypical Meningioma\|Choroid Plexus Neoplasms\|Pineal Tumor\|Diffuse Astrocytoma\|Glial Tumor	Chimerix\|National Institutes of Health (NIH)	October 26 2020	Phase 1

References

Chemical Information & Solubility

Molecular Weight	408.44	Formula	C₂₃H₂₂F₂N₄O
CAS No.	1638178-87-6	SDF	--
Smiles	FC1=CC(=C(CN2C(=O)C3=C(CCN(CC4=CC=CC=C4)C3)N5CCN=C25)C=C1)F
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 82 mg/mL ( (200.76 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 27 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):